文献速递关节外科

多剂口服氨甲环酸联合加速康复方案在初次全膝关节置换术中的血液保护疗效:一项随机对照试验

Blood-conserving efficacy of multiple doses of oral tranexamic acid associated with an enhanced-recovery programme in primary total knee arthroplasty: a randomized controlled trial.
PubMed 文献 · Bone Joint J · 2018-01-01

这项随机对照试验将200例初次全膝关节置换术患者分为四组,比较术前单剂2.0 g口服氨甲环酸后不同术后追加方案对失血的影响。结果显示,术后追加两剂或三剂可显著减少失血量,其中术后追加两剂是临床起效的最低必要方案,追加三剂则使失血量降至最低。

要点

  • 与术前单剂相比,术后追加两剂或三剂口服氨甲环酸可显著减少全膝关节置换术后的总失血量与隐性失血。
  • 术后追加两剂方案即达到临床疗效的最低必要方案,追加三剂方案使失血量下降最多。
  • C组与D组在总失血量、隐性失血及血红蛋白下降幅度三项指标上均无差异。

核心结论

  • 在术前单剂口服氨甲环酸基础上增加术后两剂或三剂,可显著减少初次全膝关节置换术的失血量。
  • 术后追加两剂是初次单侧全膝关节置换术中获得临床疗效的最低必要方案。
  • 术后追加三剂方案使失血量下降最多。

研究设计与样本

  • 随机对照试验,纳入200例患者,随机分为A、B、C、D四组,A组为术前2小时口服单剂2.0 g氨甲环酸,B、C、D组在术前单剂基础上分别于术后追加一剂、两剂、三剂口服1.0 g氨甲环酸。
  • 所有患者均遵循常规加速康复方案,主要结局指标为总失血量,次要结局指标包括隐性失血、血红蛋白水平下降、输血率及不良事件。

主要发现

  • C组(661.1 ml,标准差262.4)与D组(597.7 ml,标准差219.6)的平均总失血量显著低于A组和B组。
  • 平均隐性失血B组699.2 ml、C组533.1 ml、D组469.9 ml,均显著低于A组(分别为P=0.006、P<0.001、P<0.001)。
  • 血红蛋白水平下降幅度C组(2.22 ml,标准差0.91)与D组(2.04 ml,标准差0.95)低于A组和B组。
  • C组与D组在上述三项指标上均无差异。

关键数值与推荐

  • A组:术前2小时口服单剂2.0 g氨甲环酸;B组:术前单剂后术后3小时口服1.0 g;C组:术前单剂后术后3小时和9小时各口服1.0 g;D组:术前单剂后术后3小时、9小时和15小时各口服1.0 g。
  • 总失血量:C组661.1 ml(标准差262.4),D组597.7 ml(标准差219.6),均显著低于A组和B组。
  • 隐性失血:B组699.2 ml(P=0.006)、C组533.1 ml(P<0.001)、D组469.9 ml(P<0.001),均显著低于A组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to identify the most effective regimen of multiple doses of oral tranexamic acid (TXA) in achieving maximum reduction of blood loss in total knee arthroplasty (TKA). PATIENTS AND METHODS: In this randomized controlled trial, 200 patients were randomized to receive a single dose of 2.0 g of TXA orally two hours preoperatively (group A), a single dose of TXA followed by 1.0 g orally three hours postoperatively (group B), a single dose of TXA followed by 1.0 g three and nine hours postoperatively (group C), or a single dose of TXA followed by 1.0 g orally three, nine, and 15 hours postoperatively (group D). All patients followed a routine enhanced-recovery protocol. The primary outcome measure was the total blood loss. Secondary outcome measures were hidden blood loss (HBL), reduction in the level of haemoglobin, the rate of transfusion and adverse events. RESULTS: Groups C (661.1 ml, sd 262.4) and D (597.7 ml, sd 219.6) had significantly lower mean total blood loss compared with groups A and B. The mean HBL was significantly lower in groups B (699.2 ml), C (533.1 ml) and D (469.9 ml) than in group A (p = 0.006, p < 0.001, and p < 0.001, respectively). Groups C (2.22 ml, sd 0.91) and D (2.04 ml, sd 0.95) had a lower reduction in the level of haemoglobin than groups A and B. However, there were no differences between groups C and D in relation to the three parameters. CONCLUSION: The addition of two or three postoperative doses of TXA to one preoperative dose produced a significant reduction in blood loss. The two-dose postoperative regimen is the least necessary regimen for clinical efficacy in primary unilateral TKA. The three-dose regimen produced maximum reduction of blood loss. Cite this article: Bone Joint J 2018;100-B:1025-32.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Wang D, Wang HY, Luo ZY, et al. Blood-conserving efficacy of multiple doses of oral tranexamic acid associated with an enhanced-recovery programme in primary total knee arthroplasty: a randomized controlled trial. Bone Joint J. 2018. PMID: 30062946. doi:10.1302/0301-620X.100B8.BJJ-2017-1598.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。